BioNTech Aktie
WKN DE: A2PSR2 / ISIN: US09075V1026
|
20.09.2024 14:42:55
|
CHMP Recommends Marketing Authorization For Pfizer, BioNTech's Omicron KP.2-adapted COVID-19 Vaccine
(RTTNews) - Pfizer (PFE) and BioNTech SE (BNTX) announced that the CHMP of the European Medicines Agency has recommended marketing authorization for the companies' Omicron KP.2-adapted monovalent COVID-19 vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The European Commission will review the CHMP's recommendation.
In July 2024, the EC granted marketing authorization for Pfizer and BioNTech's Omicron JN.1-adapted COVID-19 vaccine. In the U.S., the FDA approved the companies' Omicron KP.2-adapted COVID-19 vaccine for individuals 12 years of age and older and granted emergency use authorization for individuals 6 months through 11 years of age on August 22, 2024.
For More Such Health News, visit rttnews.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu BioNTech (ADRs)mehr Nachrichten
Analysen zu BioNTech (ADRs)mehr Analysen
| 12.11.25 | BioNTech Buy | Jefferies & Company Inc. | |
| 07.11.25 | BioNTech Neutral | UBS AG | |
| 03.11.25 | BioNTech Buy | Jefferies & Company Inc. | |
| 22.08.25 | BioNTech Neutral | UBS AG | |
| 05.08.25 | BioNTech Buy | Deutsche Bank AG |
Aktien in diesem Artikel
| BioNTech (ADRs) | 89,90 | 1,01% |
|
| Pfizer Inc. | 21,81 | -2,98% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.